Last reviewed · How we verify

Palonosetron (Group P) — Competitive Intelligence Brief

Palonosetron (Group P) (Palonosetron (Group P)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Oncology, Gastroenterology.

marketed 5-HT3 receptor antagonist 5-HT3 receptor Oncology, Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Palonosetron (Group P) (Palonosetron (Group P)) — University of Malaya. Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Palonosetron (Group P) TARGET Palonosetron (Group P) University of Malaya marketed 5-HT3 receptor antagonist 5-HT3 receptor
Trintellix vortioxetine Takeda marketed Serotonin modulator and stimulator (SMS); SSRI-like agent Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor 2013-01-01
ondansetron and dyclonine hydrochloride ondansetron and dyclonine hydrochloride Peking Union Medical College Hospital marketed 5-HT3 receptor antagonist with local anesthetic 5-HT3 receptor; local anesthetic (sodium channel blockade)
Ondansetron orodispersible film once Ondansetron orodispersible film once Chongqing University Cancer Hospital marketed 5-HT3 receptor antagonist 5-HT3 receptor
Mirtazapine Tablets Mirtazapine Tablets National Institute of Mental Health, Dhaka marketed Tetracyclic antidepressant Alpha-2 adrenergic receptor, 5-HT2 receptor, 5-HT3 receptor
Aprepitant plus Ondansetron Aprepitant plus Ondansetron University of Pittsburgh marketed NK1 receptor antagonist + 5-HT3 receptor antagonist combination NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
Ramosetron, Aprepitant, Dexamethasone Ramosetron, Aprepitant, Dexamethasone Hallym University Medical Center marketed 5-HT3 antagonist / NK1 antagonist / corticosteroid combination 5-HT3 receptor, NK1 receptor, glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

  1. Helsinn Healthcare SA · 4 drugs in this class
  2. LG Life Sciences · 3 drugs in this class
  3. University of Malaya · 2 drugs in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Hamad Medical Corporation · 1 drug in this class
  6. Eye & ENT Hospital of Fudan University · 1 drug in this class
  7. Instituto Mexicano del Seguro Social · 1 drug in this class
  8. Chongqing University Cancer Hospital · 1 drug in this class
  9. Merck Sharp & Dohme LLC · 1 drug in this class
  10. MonoSol Rx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Palonosetron (Group P) — Competitive Intelligence Brief. https://druglandscape.com/ci/palonosetron-group-p. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: